Peer-influenced content. Sources you trust. No registration required. This is HCN.
Annals of Internal Medicine
The OSPREY trial puts proximal hypoglossal nerve stimulation on the map for moderate-to-severe OSA, with strong short-term numbers and the limitations a small unblinded RCT carries.
Neurology April 30th 2026
Medical Professionals Reference (MPR)
“With two large phase 3 studies now demonstrating a consistent and significant efficacy profile for AD109, we are closer to delivering the first oral pharmacotherapy for over 80 million US adults with OSA.”
Family Medicine/General Practice August 20th 2025